Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enveric Biosciences, Inc.AMRH · Entity 8193 | Director | February 14, 2018 | February 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enveric Biosciences, Inc.
Report date February 14, 2018 · Filed February 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 84,923 |
Reported balance
After 2018-02-14 transaction · row 1
1 source rowRow 1 · 2018-02-14 · Other · Acquired 7,381 · Balance 84,923 F1: Represents shares granted to the Reporting Person by the Issuer pursuant to the Issuer's 2015 Equity Incentive Award Plan in connection with the resolution of 2017 directors' fee payments owed by the Issuer to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares granted to the Reporting Person by the Issuer pursuant to the Issuer's 2015 Equity Incentive Award Plan in connection with the resolution of 2017 directors' fee payments owed by the Issuer to the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2018 Filed Feb 15, 2018 22:38 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | OtherCommon Stock | 7,381 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-18-000703 · form410211002lan_02152018.xml · nonDerivative · entry 1 Langer Arthur M · CIK 0001643882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,923 F1 · kind: Represents shares granted to the Reporting Person by the Issuer pursuant to the Issuer's 2015 Equity Incentive Award Plan in connection with the resolution of 2017 directors' fee payments owed by the Issuer to the Reporting Person. F1 · price: Represents shares granted to the Reporting Person by the Issuer pursuant to the Issuer's 2015 Equity Incentive Award Plan in connection with the resolution of 2017 directors' fee payments owed by the Issuer to the Reporting Person. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 21:42 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionRestricted Stock Unit · Derivative | 7,680 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-18-000047 · form410211002lan_01032018.xml · derivative · entry 2 Langer Arthur M · CIK 0001643882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. On January 1, 2018, the RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F1 · derivative.exercise_price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. On January 1, 2018, the RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F1 · derivative.exercise_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. On January 1, 2018, the RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F1 · derivative.expiration_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. On January 1, 2018, the RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 21:42 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 7,680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-18-000047 · form410211002lan_01032018.xml · nonDerivative · entry 1 Langer Arthur M · CIK 0001643882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. On January 1, 2018, the RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. Read SEC document |
| May 19, 2017 Filed May 23, 2017 22:24 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionRestricted Stock Unit · Derivative | 4,992 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-001622 · form410211002d_05232017.xml · derivative · entry 2 Langer Arthur M · CIK 0001643882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,992 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · security: On May 19, 2017, 4,992 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.exercise_price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_price: On May 19, 2017, 4,992 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.exercise_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_date: On May 19, 2017, 4,992 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.expiration_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.expiration_date: On May 19, 2017, 4,992 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. Read SEC document |
| May 19, 2017 Filed May 23, 2017 22:24 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 4,992 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-17-001622 · form410211002d_05232017.xml · nonDerivative · entry 1 Langer Arthur M · CIK 0001643882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,862 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · price: On May 19, 2017, 4,992 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. Read SEC document |
| May 01, 2017 Filed May 3, 2017 22:21 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionRestricted Stock Unit · Derivative | 7,680 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-001276 · form410211002d_05032017.xml · derivative · entry 3 Langer Arthur M · CIK 0001643882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. Read SEC document |
| May 01, 2017 Filed May 3, 2017 22:21 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Tax withholdingCommon Stock | 2,688 | $6.59 | $17,713.92 |
DisclosureSEC source: 0000921895-17-001276 · form410211002d_05032017.xml · nonDerivative · entry 2 Langer Arthur M · CIK 0001643882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,862 F2 · shares: Represents number of shares withheld by the Issuer for the payment of taxes. No shares of Common Stock were sold by the Reporting Person in connection with this transaction. The Reporting Person will retain the net number of shares issued upon the settlement of the RSUs. F3 · price: Closing market price of the Issuer's common stock on the transaction date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 22:21 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 7,680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-17-001276 · form410211002d_05032017.xml · nonDerivative · entry 1 Langer Arthur M · CIK 0001643882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. Read SEC document |
| April 11, 2017 Filed Apr 14, 2017 20:33 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantRestricted Stock Unit · Derivative | 7,680 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-001062 · form410211002e_04142017.xml · derivative · entry 3 Langer Arthur M · CIK 0001643882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,680 Underlying: Common Stock · 7,680 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: These Restricted Stock Units are scheduled to vest on January 1, 2018. F3 · derivative.expiration_date: These Restricted Stock Units are scheduled to vest on January 1, 2018. Read SEC document |
| April 11, 2017 Filed Apr 14, 2017 20:33 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantRestricted Stock Unit · Derivative | 7,680 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-001062 · form410211002e_04142017.xml · derivative · entry 2 Langer Arthur M · CIK 0001643882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,680 Underlying: Common Stock · 7,680 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: These Restricted Stock Units are scheduled to vest on May 1, 2017. F2 · derivative.expiration_date: These Restricted Stock Units are scheduled to vest on May 1, 2017. Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 21:29 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionRestricted Stock Unit · Derivative | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-000107 · form410211002b_01262017.xml · derivative · entry 3 Langer Arthur M · CIK 0001643882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,245 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · security: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.exercise_price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_price: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.exercise_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_date: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.expiration_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.expiration_date: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. Read SEC document |
| January 24, 2017 Filed Jan 26, 2017 21:29 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 14,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-17-000107 · form410211002b_01262017.xml · nonDerivative · entry 2 Langer Arthur M · CIK 0001643882 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · price: On January 24, 2017, 14,245 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.